Castle Biosciences, Inc. (CSTL) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

Earnings Reports

• Castle Biosciences (CSTL) Q2 2026: TissueCypher Volumes Surge 63% as Pipeline Expansion Accelerates
  July 31, 2026
• Castle Biosciences (CSTL) Q1 2026: Tissue Cipher Volume Up 58%, Propelling Guidance Hike
  May 07, 2026
• Castle Biosciences (CSTL) Q4 2025: TissueCypher Volume Soars 86%, Reinforcing GI Franchise Trajectory
  February 27, 2026
• Castle Biosciences (CSTL) Q3 2025: DecisionDx Melanoma Surpasses 10,000 Quarterly Reports, Fueling Guidance Raise
  November 04, 2025
• Castle Biosciences (CSTL) Q2 2025: TissueCypher Volume Up 92%, Offsetting SCC Policy Drag
  August 04, 2025
• Castle Biosciences (CSTL) Q1 2025: TissueCypher Delivers 117% Growth, GI Expansion Accelerates
  July 06, 2025

Browse all companies